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effectiveness, it will be important to evaluate the value of new treatments against 
existing comparators based on clinical and health economic and outcomes research 
evidence. The purpose of this study is to provide a comparative review of the clinical, 
economic, and patient-reported outcomes for selected targeted late-stage NSCLC 
therapies and evaluate pharmacoeconomic trends. METHODS: Sixteen targeted thera-
pies, currently approved or late pipeline, were identiﬁed for inclusion herein. A sys-
tematic review of peer-reviewed literature for Phase III studies and US pharmacoeconomic 
evaluations in support of these products was conducted using PubMed, related- 
articles, and ancestral searches. To capture preliminary/recent studies, conference 
proceedings from clinical and pharmacoeconomic research conferences were hand-
searched. An extraction grid was built to record key comparable attributes of each 
study type (e.g., study origin, methods and results) and identify trends in health eco-
nomic evidence platforms. RESULTS: We identiﬁed 70 original clinical, economic or 
patient-reported outcomes evaluations that met the inclusion/exclusion criteria. Phase 
III trials showed that progression free survival (PFS) varied by 1–2 months across 
treatments and most commonly reported adverse events varied, ranging from reports 
of pulmonary hemorrhage (bevacizumab) to rash and diarrhea (erlotinib and geﬁtinib). 
Few economic studies have been conducted in support of current treatments in the 
US; available studies have examined the cost-effectiveness of EGFR testing (erlotinib) 
and budget impact of adding new treatments to plan (erlotinib and pemetrexed). 
Inclusion of quality of life endpoints (e.g., lung cancer scale, FACT-L and EORTC) 
in trials is increasingly common. CONCLUSIONS: To date, few pharmacoeconomic 
evaluations have been published or presented at conferences in support of targeted 
NSCLC agents but current pharmacoeconomic platforms are useful for establishing 
future benchmarks for new entrants.
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OBJECTIVES: Across Europe, health technology assessment and traditional market 
access bodies are requesting more clinical evidence before allowing appropriate market 
access. These raised expectations create an imbalance between what clinical trial 
data is required for market authorization and what is required for market access, 
with greater scrutiny on response rates, QoL and, in particular, overall survival. In 
part to address this imbalance between desired and available data, industry and many 
European payers are considering risk sharing/pay-for-performance. To address this 
growing gap between regulatory and market access requirements, this research seeks 
to provide a better understanding of what payer expectations are and what is driving 
those expectations. METHODS: Oncology analog analysis and targeted primary 
research to assess the success of recently launched oncology value propositions, deﬁned 
by HTA evaluations and market access authorities. Identiﬁcation of risk sharing agree-
ments through secondary research. France and the UK are the primary markets 
researched. RESULTS: This research suggests that HTA and market access bodies 
are becoming more risk adverse and requiring additional data beyond what is needed 
for regulatory approval. CONCLUSIONS: As more and more oncology products 
come to market, offering hope and promises of improved QoL and longer survival, 
payers are increasingly conscious of the budget impact of new, highly valued agents. 
In order to provide access to these products, payers are increasingly raising data 
requirements. However, given the nature of oncology, payers’ expectations vary based 
on the stage of the disease, the level of unmet need, and the number of available 
alternatives.
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OBJECTIVES: To ﬁeld test the EVIDEM framework applying multicriteria decision 
analyses (MCDA) to support health care decisionmaking, with a private health care 
payer in South Africa. METHODS: Liquid based cytology (LBC) for cervical cancer 
screening was selected as a intervention requiring a coverage decision which would 
beneﬁt from an MCDA approach. The matrix included 15 components of decision in 
four domains (quality of evidence, disease, intervention and economics). A synthesized 
health technology assessment report tailored to investigate each component was pre-
pared. The decisionmaking committee estimated the MCDA value of LBC by assigning 
weights and scores for each matrix component. A survey instrument was administered 
to explore validity and outcomes of approach. RESULTS: Value of LBC was estimated 
at 58% of maximum value on the MCDA scale. Main contributors to value were 
relevance and validity of evidence, disease severity and risk reduction. Minor clinical 
improvement and signiﬁcant economic impact contributed little to value. On average, 
86% of committee members indicated that the same 12 components the MCDA matrix 
should always be considered. Non quantiﬁable components of decision were also 
identiﬁed and discussed. A majority of participants reported that the framework 
would improve: understanding of intervention; access to data on quality of evidence; 
consideration of key elements of decision; transparency of the decision; and under-
standability of decision by stakeholders. CONCLUSIONS: The EVIDEM framework 
provides a transparent record of how evidence and values are assessed during the 
decisionmaking process. Further testing and validation is needed to advance MCDA 
approaches in health care decisionmaking.
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BACKGROUND: In allocating resources to improve patient care, two decisions must 
be addressed: 1) whether to issue guidance on the use of a health technology consider-
ing its cost-effectiveness, and 2) whether to invest in the active implementation of such 
guidance (e.g. via education, incentives or regulation), as its clinical use does not neces-
sarily follow. Since these two decisions are related, resource allocation can be based 
on either sequential (1-by-1) or integral analysis. OBJECTIVES: To identify the pre-
ferred approach to the analysis for addressing decisions about issuing and actively 
implementing clinical guidance. APPLICATION: The application relates to the alloca-
tion of resources to metastatic hormone-refractory prostate cancer (mHRPC) in the 
UK. METHODS: An integrated Bayesian approach to decision modeling and evidence 
synthesis is adopted. Evidence on the costs and QALYs of all plausible treatment regi-
mens is combined with estimates of treatment usage and population size. Implementa-
tion costs and effects are assumed to vary between treatment options. Both sequential 
and integral analyses of resource allocation are performed. RESULTS: (preliminary): 
For cost-effectiveness thresholds £25,000–£32,000 per QALY, decisions about how 
best to improve care for mHRPC patients differ between the alternative analytic 
approaches. Based on sequential analysis, MitoxantronePrednisone is deemed cost-
effective, without actively implementing this guidance. An integral analysis reveals that 
active implementation of DocetaxelPrednisone (3 weekly) is the cost-effective option, 
yielding an additional 0.05 QALY per patient. By combining uncertain evidence on 
treatment regimens, their usage and active implementation, allowance is made for all 
uncertainty associated with resource allocation in mHRPC. CONCLUSIONS: For the 
analysis of the related decisions about 1) issuing, and 2) actively implementing clinical 
guidance, an integral approach is preferred over a sequential one. As the application 
in mHRPC demonstrates, integral analysis provides better options for improving 
patient management, more comprehensive insight in decision uncertainty and, conse-
quently, an efﬁcient allocation of resources.
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OBJECTIVES: The aim of this study was to collect comparable and reliable data on 
the chemotherapy regimens in Slovakia during the period 1999–2008. The special 
interest was paid to the trend of antineoplastic agents, endocrine therapy, immunos-
timulants and immunosuppressants usages. METHODS: Data of wholesalers (follow-
ing ATC/DDD), who are legally obliged provide this information to the Slovak 
Institute for Drug Control, was used for the analysis. The results were expressed in 
ﬁnance units (a) and deﬁned daily doses per 1000 inhabitants per day (DID). 
RESULTS: The collected data showed a dramatic increase in chemotherapy from 1999 
to 2008 in term of DID—in 1999 (17.55), in 2003 (30.33) and in 2008 (38.61). We 
can see a signiﬁcant increase in consumption of antineoplastic agents (DID)—in 1999 
(11.75), in 2003 (18.06) and in 2008 (29.77) and a noticeable increase in endocrine 
therapy—in 1999 (1.71), in 2003 (1.49) and in 2008 (2.48). Unstable consumption 
of immunostimulants—in 1999 (3.76), in 2003 (10.15) and in 2008 (5.06), and a 
moderate increase in consumption of immunosuppressants—in 1999 (0.31), in 2003 
(0.62) and in 2008 (1.29) can be seen from this analysis. Results showed a dramatic 
increase in consumptions from the ﬁnancial perspective—antineoplastic agents in 1999 
(a5,440,000), in 2003 (a16,599,000) and in 2008 (a97,915,000), endocrine therapy 
in 1999 (a3,292,000), in 2003 (a6,779,000) and in 2008 (a14,186,000), immunos-
timulants in 1999 (a5,248,000), in 2003 (a15,538,000) and in 2008 (a24,178,000), 
immunosuppressive agents in 1999 (a3,867,000), in 2003 (a8,109,000) and in 2008 
(a28,288,000). CONCLUSIONS: Inseparable components of the Slovak drug policy 
must be viewed realistically with regard to chemotherapy regimens, which cause huge 
ﬁnancial expenditures within the Slovak health care budget.
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OBJECTIVES: To evaluate the relationship between the average out of pocket cost 
(OPC) paid and the total prescription volume (TRx) for oral antineoplastics compared 
to a market basket of commonly utilized oral drugs. Is drug utilization more sensitive 
to OPC changes when there is greater competition and/or when the ailments treated 
by those drugs are less acute? We hypothesized an inverse proportional relationship 
between OPC and TRx. METHODS: We obtained monthly OPC data and TRx 
data from SDI’s VONA and VOPA databases from January 2007-April 2009. We 
